Risk factors associated with trastuzumab-induced cardiotoxicity in patients with human epidermal growth factor receptor 2-positive breast cancer

9Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Context: Although trastuzumab is a highly effective and selective targeted therapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, the drug-induced cardiotoxicity may confine its usefulness in patients. Aim: To explore risk factors associated with the development of cardiotoxicity in patients with HER2-positive breast cancer. Settings and Design: A retrospective review of medical records and chart review for all patients with breast cancer treated with trastuzumab was conducted at King Abdulaziz Medical City and King Abdullah Specialized Children Hospital in Riyadh, Kingdom of Saudi Arabia, between October 2015 and February 2018. Patients with declined left ventricular ejection fraction, either with or without cardiac symptoms, were recognized as those with cardiotoxicity due to trastuzumab administration. Results: A total of 146 patients were included in the study with an average age of 52.7 (standard deviation = 12.2) years. Thirty-two (21.9%) patients developed cardiotoxicity. However, only 24 (16.4%) were symptomatic with an apparent heart failure but it did not necessitate interruption of trastuzumab therapy. The majority of patients had prior underlying cardiovascular diseases. This study identified unilateral tumor site (62.5%), breast surgery (37.5%), and concomitant taxane chemotherapy (62.5%) as the main risk factors associated with significant increase in cardiotoxicity in patients with breast cancer (with P values of 0.0269, 0.0482, and 0.0225, respectively). Conclusion: The majority of patients (more than 90%) developed cardiotoxicity after completion of chemotherapy. However, recruiting a larger sample size should be warranted to confirm or negate these findings.

References Powered by Scopus

Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials

1949Citations
N/AReaders
Get full text

Cardiac dysfunction in the trastuzumab clinical trials experience

1375Citations
N/AReaders
Get full text

Anthracycline-Induced Cardiomyopathy. Clinical Relevance and Response to Pharmacologic Therapy

934Citations
N/AReaders
Get full text

Cited by Powered by Scopus

African Vegetables (Clerodendrum volibile Leaf and Irvingia gabonensis Seed Extracts) Effectively Mitigate Trastuzumab-Induced Cardiotoxicity in Wistar Rats

20Citations
N/AReaders
Get full text

Risks of trastuzumab-related cardiotoxicity in breast cancer patients in Taiwan

6Citations
N/AReaders
Get full text

Current perspectives of cardio-oncology: Epidemiology, adverse effects, pre-treatment screening and prevention strategies

4Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Abdel-Razaq, W., Alzahrani, M., Al Yami, M., Almugibl, F., Almotham, M., & Alregaibah, R. (2019). Risk factors associated with trastuzumab-induced cardiotoxicity in patients with human epidermal growth factor receptor 2-positive breast cancer. Journal of Pharmacy and Bioallied Sciences, 11(4), 348–354. https://doi.org/10.4103/jpbs.JPBS_276_18

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 7

70%

Researcher 3

30%

Readers' Discipline

Tooltip

Medicine and Dentistry 6

60%

Pharmacology, Toxicology and Pharmaceut... 2

20%

Chemistry 1

10%

Nursing and Health Professions 1

10%

Save time finding and organizing research with Mendeley

Sign up for free